NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms

Barry M. Kacinski, Allan G. Mayer, Bonnie L. King, Darryl Carter, Setsuko K. Chambers

Research output: Contribution to journalArticle

Abstract

In situ hybridization (ISH) analysis of 24 benign, borderline, and malignant ovarian tumor specimens revealed NEU transcript expression by epithelial elements in approximately two-thirds of the samples and high-level expression in 3 grade 3 adenocarcinomas. Immunohistochemical staining (IHC) of a total of 86 specimens (including 17 of those studied by ISH) localized NEU antigen expression to epithelial cells in 36 of 86 samples with strong membrane staining observed in 12, including 1 benign, 1 borderline serous carcinoma, 3 clear cell/endometrioid carcinomas, and 7 predominantly papillary serous carcinomas with areas of clear cell/endometrioid histology. Clinical correlation of the IHC results for the 72 Stage I-IV invasively malignant neoplasms revealed no statistically significant association of the intensity of NEU IHC staining with either relapse-free or overall survival. However, more of the patients whose tumors showed strong membrane staining for NEU antigen suffered relapses of disease by 3 and 4 years than did patients whose tumors showed weak or no membrane staining. These results suggest a role for the NEU gene product in the physiology of benign ovarian surface epithelium and the neoplastic epithelium of preinvasive borderline and some invasively malignant adenocarcinomas.

Original languageEnglish (US)
Pages (from-to)245-253
Number of pages9
JournalGynecologic Oncology
Volume44
Issue number3
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Staining and Labeling
Proteins
In Situ Hybridization
Membranes
Neoplasms
Adenocarcinoma
Epithelium
Endometrioid Carcinoma
Antigens
Recurrence
Papillary Carcinoma
Histology
Epithelial Cells
Carcinoma
Survival
Genes

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Kacinski, B. M., Mayer, A. G., King, B. L., Carter, D., & Chambers, S. K. (1992). NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecologic Oncology, 44(3), 245-253. https://doi.org/10.1016/0090-8258(92)90051-J

NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. / Kacinski, Barry M.; Mayer, Allan G.; King, Bonnie L.; Carter, Darryl; Chambers, Setsuko K.

In: Gynecologic Oncology, Vol. 44, No. 3, 1992, p. 245-253.

Research output: Contribution to journalArticle

Kacinski, BM, Mayer, AG, King, BL, Carter, D & Chambers, SK 1992, 'NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms', Gynecologic Oncology, vol. 44, no. 3, pp. 245-253. https://doi.org/10.1016/0090-8258(92)90051-J
Kacinski, Barry M. ; Mayer, Allan G. ; King, Bonnie L. ; Carter, Darryl ; Chambers, Setsuko K. / NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. In: Gynecologic Oncology. 1992 ; Vol. 44, No. 3. pp. 245-253.
@article{b94a5b78d5fd4588a86ef756d266002e,
title = "NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms",
abstract = "In situ hybridization (ISH) analysis of 24 benign, borderline, and malignant ovarian tumor specimens revealed NEU transcript expression by epithelial elements in approximately two-thirds of the samples and high-level expression in 3 grade 3 adenocarcinomas. Immunohistochemical staining (IHC) of a total of 86 specimens (including 17 of those studied by ISH) localized NEU antigen expression to epithelial cells in 36 of 86 samples with strong membrane staining observed in 12, including 1 benign, 1 borderline serous carcinoma, 3 clear cell/endometrioid carcinomas, and 7 predominantly papillary serous carcinomas with areas of clear cell/endometrioid histology. Clinical correlation of the IHC results for the 72 Stage I-IV invasively malignant neoplasms revealed no statistically significant association of the intensity of NEU IHC staining with either relapse-free or overall survival. However, more of the patients whose tumors showed strong membrane staining for NEU antigen suffered relapses of disease by 3 and 4 years than did patients whose tumors showed weak or no membrane staining. These results suggest a role for the NEU gene product in the physiology of benign ovarian surface epithelium and the neoplastic epithelium of preinvasive borderline and some invasively malignant adenocarcinomas.",
author = "Kacinski, {Barry M.} and Mayer, {Allan G.} and King, {Bonnie L.} and Darryl Carter and Chambers, {Setsuko K.}",
year = "1992",
doi = "10.1016/0090-8258(92)90051-J",
language = "English (US)",
volume = "44",
pages = "245--253",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms

AU - Kacinski, Barry M.

AU - Mayer, Allan G.

AU - King, Bonnie L.

AU - Carter, Darryl

AU - Chambers, Setsuko K.

PY - 1992

Y1 - 1992

N2 - In situ hybridization (ISH) analysis of 24 benign, borderline, and malignant ovarian tumor specimens revealed NEU transcript expression by epithelial elements in approximately two-thirds of the samples and high-level expression in 3 grade 3 adenocarcinomas. Immunohistochemical staining (IHC) of a total of 86 specimens (including 17 of those studied by ISH) localized NEU antigen expression to epithelial cells in 36 of 86 samples with strong membrane staining observed in 12, including 1 benign, 1 borderline serous carcinoma, 3 clear cell/endometrioid carcinomas, and 7 predominantly papillary serous carcinomas with areas of clear cell/endometrioid histology. Clinical correlation of the IHC results for the 72 Stage I-IV invasively malignant neoplasms revealed no statistically significant association of the intensity of NEU IHC staining with either relapse-free or overall survival. However, more of the patients whose tumors showed strong membrane staining for NEU antigen suffered relapses of disease by 3 and 4 years than did patients whose tumors showed weak or no membrane staining. These results suggest a role for the NEU gene product in the physiology of benign ovarian surface epithelium and the neoplastic epithelium of preinvasive borderline and some invasively malignant adenocarcinomas.

AB - In situ hybridization (ISH) analysis of 24 benign, borderline, and malignant ovarian tumor specimens revealed NEU transcript expression by epithelial elements in approximately two-thirds of the samples and high-level expression in 3 grade 3 adenocarcinomas. Immunohistochemical staining (IHC) of a total of 86 specimens (including 17 of those studied by ISH) localized NEU antigen expression to epithelial cells in 36 of 86 samples with strong membrane staining observed in 12, including 1 benign, 1 borderline serous carcinoma, 3 clear cell/endometrioid carcinomas, and 7 predominantly papillary serous carcinomas with areas of clear cell/endometrioid histology. Clinical correlation of the IHC results for the 72 Stage I-IV invasively malignant neoplasms revealed no statistically significant association of the intensity of NEU IHC staining with either relapse-free or overall survival. However, more of the patients whose tumors showed strong membrane staining for NEU antigen suffered relapses of disease by 3 and 4 years than did patients whose tumors showed weak or no membrane staining. These results suggest a role for the NEU gene product in the physiology of benign ovarian surface epithelium and the neoplastic epithelium of preinvasive borderline and some invasively malignant adenocarcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0026508152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026508152&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(92)90051-J

DO - 10.1016/0090-8258(92)90051-J

M3 - Article

C2 - 1347282

AN - SCOPUS:0026508152

VL - 44

SP - 245

EP - 253

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -